Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Nephrology
  • Nephrology News
  • Finerenone and...

Finerenone and Empagliflozin Combo Significantly Reduces Albuminuria in CKD with T2D: new data from CONFIDENCE Trial

Dr. Kamal Kant KohliWritten by Dr. Kamal Kant Kohli Published On 2025-06-06T21:00:54+05:30  |  Updated On 6 Jun 2025 9:01 PM IST
Finerenone and Empagliflozin Combo Significantly Reduces Albuminuria in CKD with T2D: new data from CONFIDENCE Trial
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

New findings from the CONFIDENCE trial show that combination therapy with finerenone and empagliflozin leads to significantly greater reductions in albuminuria compared to either drug alone in patients with chronic kidney disease and type 2 diabetes. Results were presented at the 62nd ERA Congress and published in the New England Journal of Medicine.

For many patients, albuminuria is the earliest sign of CKD.2 Increased levels of albuminuria is linked to a faster rate of CKD progression in both diabetic and nondiabetic kidney disease patients.

Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist (nsMRA), and SGLT2 inhibitors like empagliflozin have independently demonstrated efficacy in delaying CKD progression and improving cardiovascular outcomes. The CONFIDENCE study is the first randomised trial to test the hypothesis that early, simultaneous use of both agents would provide superior reduction in urinary albumin-to-creatinine ratio (UACR) over 6 months, compared to either drug alone.

This phase 2, multicentre, randomised, double-blind trial enrolled 818 adults with CKD (eGFR 30–90 ml/min/1.73 m²) and T2D, with a UACR between 100 and <5,000 mg/g, all receiving a maximally tolerated dose of a renin–angiotensin system inhibitor for at least one month. Participants were randomised in a 1:1:1 ratio to receive empagliflozin 10 mg once daily + placebo, finerenone 10 or 20 mg once daily + placebo, or a combination of finerenone and empagliflozin, with doses adjusted based on baseline eGFR. Baseline clinical characteristics were published in Nephrology Dialysis Transplantation on 7 February 2025.

Randomisation was stratified by eGFR (< or ≥60 ml/min/1.73 m²) and UACR (≤ or >850 mg/g). Patients were recruited from 143 sites across 14 countries between July 2022 and August 2024, ensuring a diverse population with a high burden of comorbidities, including cardiovascular disease (28%), diabetic retinopathy (16%), and heart failure (4%).

At Day 180, the combination group showed a 52% median reduction in UACR from baseline, which was significantly greater than reductions seen with either drug alone. Specifically, UACR was reduced by an additional 29% compared to finerenone alone (P<0.001) and by 32% compared to empagliflozin alone (P<0.001).

“The CONFIDENCE study delivers the clear message that simultaneous initiation of finerenone and empagliflozin led to an early and additive reduction in UACR of 52% in patients with CKD and T2D, which was significantly greater than with either treatment alone,” said lead researcher Dr. Rajiv Agarwal.

“In other chronic conditions like heart failure or hypertension, we’re moving away from the traditional stepwise approach toward upfront combination therapy,” Dr. Agarwal explained. “In CONFIDENCE, 70% of patients on both therapies achieved the ADA-recommended UACR reduction target of >30%. Since UACR is a key mediator of kidney and cardiovascular outcomes, these results are highly relevant for clinical decision-making.”

Importantly, combination therapy was well tolerated, with no unexpected safety signals. Rates of symptomatic hypotension, acute kidney injury, and hyperkalemia leading to treatment discontinuation were low.

The findings support a paradigm shift toward early, dual-pathway intervention in CKD and T2D, offering clinicians a new, evidence-based strategy to optimise outcomes in a population at high risk of kidney and cardiovascular complications.

Reference:

Combination finerenone and empagliflozin shows superior efficacy in reducing albuminuria in chronic kidney disease and type 2 diabetes patients, Beyond, Meeting: 62nd ERA Congress.

New England Journal of Medicinefinerenoneempagliflozinchronic kidney diseasealbuminuriatype 2 diabetes
Source : New England Journal of Medicine
Dr. Kamal Kant Kohli
Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

Show Full Article
Next Story

Editorial

Featured image representing thinking

Is Pharma Marketing Going Through "Thinking Recession"?

Beyond BMI: Why Pioglitazone Deserves a Place in Managing Thin-Fat Type 2 Diabetes in India

Beyond BMI: Why Pioglitazone Deserves a Place in Managing 'Thin-Fat' Type 2 Diabetes in India

How to Improve Adherence in Hypertensive Patients? Bridging the Gap with CONNECT Tool

How to Improve Adherence in Hypertensive Patients? Bridging the Gap with CONNECT Tool

Vestibular Migraine: Clinical Update and Role of Buccal Prochlorperazine

Vestibular Migraine: Clinical Update and Role of Buccal Prochlorperazine

U.S. FDA Drug Safety Alert: Warning Issued for Severe Itching After Stopping Long-Term Cetirizine or Levocetirizine Use

U.S. FDA Drug Safety Alert: Warning Issued for Severe Itching After Stopping Long-Term Cetirizine or...

View All

Journal Club Today

Overemphasis on Weight Loss May Harm Patients: BMJ Study Finds

Overemphasis on Weight Loss May Harm Patients: BMJ Study Finds

View All

Health News Today

Health Bulletin 28/June/2025

Health Bulletin 28/June/2025

View All
© 2022 All Rights Reserved.
Powered By: Hocalwire
X
We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok